Skip to main content
Erschienen in: Clinical & Experimental Metastasis 7/2013

01.10.2013 | Research Paper

Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells

verfasst von: Dhivya R. Sudhan, Dietmar W. Siemann

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Metastasis remains the major cause of therapeutic failure, poor prognosis and high mortality in breast and prostate cancer patients. Aberrant microenvironments including hypoxia and acidic pH are common features of most solid tumors that have been long associated with enhanced metastasis and poor patient outcomes. Novel approaches to reduce metastatic incidences and improve overall survival of cancer patients clearly are needed. The crucial role of Cathepsin L (CTSL) in the dissemination of tumor cells has led to the development of novel cathepsin L inhibition strategies. The present study evaluated the ability of KGP94, a small molecule inhibitor of CTSL, to impair the metastatic phenotype of prostate (PC-3ML) and breast (MDA-MB-231) cancer cells both under normal and aberrant microenvironmental conditions. To assess the role of CTSL in hypoxia and acidosis triggered metastasis associated cell functions, secreted CTSL levels were determined under conditions pertinent to the tumor microenvironment. Acute exposures to hypoxic or acidic conditions significantly elevated secreted CTSL levels either through an increase in intracellular CTSL levels or through activation of lysosomal exocytosis or both, depending on the tumor type. Increases in CTSL secretion closely paralleled enhanced tumor cell migration and invasion suggesting that CTSL could be an essential factor in tumor microenvironment triggered metastasis. Importantly, KGP94 treatment led to marked attenuation of tumor cell invasion and migration under both normal and aberrant microenvironmental conditions suggesting that it may have significant utility as an anti-metastatic agent.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef
2.
Zurück zum Zitat Duffy MJ (1992) The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10:145–155PubMedCrossRef Duffy MJ (1992) The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10:145–155PubMedCrossRef
3.
Zurück zum Zitat Gocheva V, Joyce JA (2007) Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6:60–64PubMedCrossRef Gocheva V, Joyce JA (2007) Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6:60–64PubMedCrossRef
4.
Zurück zum Zitat Laufs S, Schumacher J, Allgayer H (2006) Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 5:1760–1771PubMedCrossRef Laufs S, Schumacher J, Allgayer H (2006) Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 5:1760–1771PubMedCrossRef
5.
Zurück zum Zitat Chauhan SS, Goldstein LJ, Gottesman MM (1991) Expression of cathepsin L in human tumors. Cancer Res 51:1478–1481PubMed Chauhan SS, Goldstein LJ, Gottesman MM (1991) Expression of cathepsin L in human tumors. Cancer Res 51:1478–1481PubMed
6.
Zurück zum Zitat Gottesman MM, Sobel ME (1980) Tumor promoters and Kirsten sarcoma virus increase synthesis of a secreted glycoprotein by regulating levels of translatable mRNA. Cell 19:449–455PubMedCrossRef Gottesman MM, Sobel ME (1980) Tumor promoters and Kirsten sarcoma virus increase synthesis of a secreted glycoprotein by regulating levels of translatable mRNA. Cell 19:449–455PubMedCrossRef
7.
Zurück zum Zitat Prence EM, Dong JM, Sahagian GG (1990) Modulation of the transport of a lysosomal enzyme by PDGF. J Cell Biol 110:319–326PubMedCrossRef Prence EM, Dong JM, Sahagian GG (1990) Modulation of the transport of a lysosomal enzyme by PDGF. J Cell Biol 110:319–326PubMedCrossRef
8.
Zurück zum Zitat Stearns NA, Dong JM, Pan JX, Brenner DA, Sahagian GG (1990) Comparison of cathepsin L synthesized by normal and transformed cells at the gene, message, protein, and oligosaccharide levels. Arch Biochem Biophys 283:447–457PubMedCrossRef Stearns NA, Dong JM, Pan JX, Brenner DA, Sahagian GG (1990) Comparison of cathepsin L synthesized by normal and transformed cells at the gene, message, protein, and oligosaccharide levels. Arch Biochem Biophys 283:447–457PubMedCrossRef
9.
Zurück zum Zitat Chambers AF, Colella R, Denhardt DT, Wilson SM (1992) Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells. Mol Carcinog 5:238–245PubMedCrossRef Chambers AF, Colella R, Denhardt DT, Wilson SM (1992) Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells. Mol Carcinog 5:238–245PubMedCrossRef
10.
Zurück zum Zitat Ishidoh K, Kominami E (1995) Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. Biochem Biophys Res Commun 217:624–631PubMedCrossRef Ishidoh K, Kominami E (1995) Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. Biochem Biophys Res Commun 217:624–631PubMedCrossRef
11.
Zurück zum Zitat Mason RW, Johnson DA, Barrett AJ, Chapman HA (1986) Elastinolytic activity of human cathepsin L. Biochem J 233:925–927PubMed Mason RW, Johnson DA, Barrett AJ, Chapman HA (1986) Elastinolytic activity of human cathepsin L. Biochem J 233:925–927PubMed
12.
Zurück zum Zitat Abboud-Jarrous G, Atzmon R, Peretz T et al (2008) Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 283:18167–18176PubMedCrossRef Abboud-Jarrous G, Atzmon R, Peretz T et al (2008) Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 283:18167–18176PubMedCrossRef
13.
Zurück zum Zitat Everts V, Korper W, Hoeben KA et al (2006) Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 21:1399–1408PubMedCrossRef Everts V, Korper W, Hoeben KA et al (2006) Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 21:1399–1408PubMedCrossRef
14.
Zurück zum Zitat Laurent-Matha V, Derocq D, Prebois C, Katunuma N, Liaudet-Coopman E (2006) Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B. J Biochem 139:363–371PubMedCrossRef Laurent-Matha V, Derocq D, Prebois C, Katunuma N, Liaudet-Coopman E (2006) Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B. J Biochem 139:363–371PubMedCrossRef
15.
Zurück zum Zitat Gillies RJ, Schornack PA, Secomb TW, Raghunand N (1999) Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1:197–207PubMedCrossRef Gillies RJ, Schornack PA, Secomb TW, Raghunand N (1999) Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1:197–207PubMedCrossRef
16.
Zurück zum Zitat Lunt SJ, Chaudary N, Hill RP (2009) The tumor microenvironment and metastatic disease. Clin Exp Metastasis 26:19–34PubMedCrossRef Lunt SJ, Chaudary N, Hill RP (2009) The tumor microenvironment and metastatic disease. Clin Exp Metastasis 26:19–34PubMedCrossRef
17.
Zurück zum Zitat Schwickert G, Walenta S, Sundfor K, Rofstad EK, Mueller-Klieser W (1995) Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 55:4757–4759PubMed Schwickert G, Walenta S, Sundfor K, Rofstad EK, Mueller-Klieser W (1995) Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 55:4757–4759PubMed
18.
Zurück zum Zitat Walenta S, Salameh A, Lyng H et al (1997) Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol 150:409–415PubMed Walenta S, Salameh A, Lyng H et al (1997) Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol 150:409–415PubMed
19.
20.
Zurück zum Zitat Cairns RA, Kalliomaki T, Hill RP (2001) Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 61:8903–8908PubMed Cairns RA, Kalliomaki T, Hill RP (2001) Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 61:8903–8908PubMed
21.
Zurück zum Zitat Rofstad EK, Galappathi K, Mathiesen B, Ruud EB (2007) Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res 13:1971–1978PubMedCrossRef Rofstad EK, Galappathi K, Mathiesen B, Ruud EB (2007) Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res 13:1971–1978PubMedCrossRef
22.
Zurück zum Zitat Zajc I, Sever N, Bervar A, Lah TT (2002) Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. Cancer Lett 187:185–190PubMedCrossRef Zajc I, Sever N, Bervar A, Lah TT (2002) Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. Cancer Lett 187:185–190PubMedCrossRef
23.
Zurück zum Zitat Kishore Kumar GD, Chavarria GE, Charlton-Sevcik AK et al (2010) Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett 20:1415–1419PubMedCrossRef Kishore Kumar GD, Chavarria GE, Charlton-Sevcik AK et al (2010) Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett 20:1415–1419PubMedCrossRef
24.
Zurück zum Zitat Chavarria GE, Horsman MR, Arispe WM et al (2012) Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L. Eur J Med Chem 58:568–572PubMedCrossRef Chavarria GE, Horsman MR, Arispe WM et al (2012) Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L. Eur J Med Chem 58:568–572PubMedCrossRef
25.
Zurück zum Zitat Wang M, Stearns ME (1991) Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D mice. Differentiation 48:115–125PubMedCrossRef Wang M, Stearns ME (1991) Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D mice. Differentiation 48:115–125PubMedCrossRef
26.
Zurück zum Zitat Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-435 cells are derived from M14 melanoma cells–a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13–19PubMedCrossRef Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-435 cells are derived from M14 melanoma cells–a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13–19PubMedCrossRef
27.
Zurück zum Zitat Chambers AF (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69:5292–5293PubMedCrossRef Chambers AF (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69:5292–5293PubMedCrossRef
28.
Zurück zum Zitat Urquidi V, Sloan D, Kawai K et al (2002) Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 8:61–74PubMed Urquidi V, Sloan D, Kawai K et al (2002) Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 8:61–74PubMed
29.
Zurück zum Zitat Dai Y, Siemann DW (2012) Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer 12:198PubMedCrossRef Dai Y, Siemann DW (2012) Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer 12:198PubMedCrossRef
30.
Zurück zum Zitat Dai Y, Bae K, Siemann DW (2011) Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int J Radiat Oncol Biol Phys 81:521–528PubMedCrossRef Dai Y, Bae K, Siemann DW (2011) Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int J Radiat Oncol Biol Phys 81:521–528PubMedCrossRef
31.
Zurück zum Zitat Cuvier C, Jang A, Hill RP (1997) Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L+B) secretion. Clin Exp Metastasis 15:19–25PubMedCrossRef Cuvier C, Jang A, Hill RP (1997) Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L+B) secretion. Clin Exp Metastasis 15:19–25PubMedCrossRef
32.
Zurück zum Zitat Lankelma JM, Voorend DM, Barwari T et al (2010) Cathepsin L, target in cancer treatment? Life Sci 86:225–233PubMedCrossRef Lankelma JM, Voorend DM, Barwari T et al (2010) Cathepsin L, target in cancer treatment? Life Sci 86:225–233PubMedCrossRef
33.
Zurück zum Zitat Leto G, Sepporta MV, Crescimanno M, Flandina C, Tumminello FM (2010) Cathepsin L in metastatic bone disease: therapeutic implications. Biol Chem 391:655–664PubMedCrossRef Leto G, Sepporta MV, Crescimanno M, Flandina C, Tumminello FM (2010) Cathepsin L in metastatic bone disease: therapeutic implications. Biol Chem 391:655–664PubMedCrossRef
34.
Zurück zum Zitat Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP (1994) Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 31:325–335PubMedCrossRef Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP (1994) Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 31:325–335PubMedCrossRef
35.
Zurück zum Zitat Turk B, Turk D, Turk V (2000) Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 1477:98–111PubMedCrossRef Turk B, Turk D, Turk V (2000) Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 1477:98–111PubMedCrossRef
36.
Zurück zum Zitat Carini R, Castino R, De Cesaris MG et al (2004) Preconditioning-induced cytoprotection in hepatocytes requires Ca(2+)-dependent exocytosis of lysosomes. J Cell Sci 117:1065–1077PubMedCrossRef Carini R, Castino R, De Cesaris MG et al (2004) Preconditioning-induced cytoprotection in hepatocytes requires Ca(2+)-dependent exocytosis of lysosomes. J Cell Sci 117:1065–1077PubMedCrossRef
37.
Zurück zum Zitat Lee M, Fridman R, Mobashery S (2004) Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev 33:401–409PubMedCrossRef Lee M, Fridman R, Mobashery S (2004) Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev 33:401–409PubMedCrossRef
38.
Zurück zum Zitat Dong JM, Prence EM, Sahagian GG (1989) Mechanism for selective secretion of a lysosomal protease by transformed mouse fibroblasts. J Biol Chem 264:7377–7383PubMed Dong JM, Prence EM, Sahagian GG (1989) Mechanism for selective secretion of a lysosomal protease by transformed mouse fibroblasts. J Biol Chem 264:7377–7383PubMed
39.
Zurück zum Zitat Gocheva V, Zeng W, Ke D et al (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20:543–556PubMedCrossRef Gocheva V, Zeng W, Ke D et al (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20:543–556PubMedCrossRef
40.
Zurück zum Zitat Foekens JA, Kos J, Peters HA et al (1998) Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 16:1013–1021PubMed Foekens JA, Kos J, Peters HA et al (1998) Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 16:1013–1021PubMed
41.
Zurück zum Zitat Thomssen C, Schmitt M, Goretzki L et al (1995) Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin Cancer Res 1:741–746PubMed Thomssen C, Schmitt M, Goretzki L et al (1995) Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin Cancer Res 1:741–746PubMed
42.
Zurück zum Zitat Friedrich B, Jung K, Lein M et al (1999) Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. Eur J Cancer 35:138–144PubMedCrossRef Friedrich B, Jung K, Lein M et al (1999) Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. Eur J Cancer 35:138–144PubMedCrossRef
43.
Zurück zum Zitat Kos J, Krasovec M, Cimerman N et al (2000) Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res 6:505–511PubMed Kos J, Krasovec M, Cimerman N et al (2000) Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res 6:505–511PubMed
44.
Zurück zum Zitat Strojan P, Oblak I, Svetic B, Smid L, Kos J (2004) Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis. Br J Cancer 90:1961–1968PubMedCrossRef Strojan P, Oblak I, Svetic B, Smid L, Kos J (2004) Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis. Br J Cancer 90:1961–1968PubMedCrossRef
45.
Zurück zum Zitat Kolwijck E, Massuger LF, Thomas CM et al (2010) Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors. J Cancer Res Clin Oncol 136:771–778PubMedCrossRef Kolwijck E, Massuger LF, Thomas CM et al (2010) Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors. J Cancer Res Clin Oncol 136:771–778PubMedCrossRef
46.
Zurück zum Zitat Ervin H, Cox JL (2005) Late stage inhibition of hematogenous melanoma metastasis by cystatin C over-expression. Cancer Cell Int 5:14PubMedCrossRef Ervin H, Cox JL (2005) Late stage inhibition of hematogenous melanoma metastasis by cystatin C over-expression. Cancer Cell Int 5:14PubMedCrossRef
47.
Zurück zum Zitat Kirschke H, Eerola R, Hopsu-Havu VK, Bromme D, Vuorio E (2000) Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells. Eur J Cancer 36:787–795PubMedCrossRef Kirschke H, Eerola R, Hopsu-Havu VK, Bromme D, Vuorio E (2000) Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells. Eur J Cancer 36:787–795PubMedCrossRef
48.
Zurück zum Zitat Yang Z, Cox JL (2007) Cathepsin L increases invasion and migration of B16 melanoma. Cancer Cell Int 7:8PubMedCrossRef Yang Z, Cox JL (2007) Cathepsin L increases invasion and migration of B16 melanoma. Cancer Cell Int 7:8PubMedCrossRef
49.
Zurück zum Zitat Fortenberry YM, Brandal S, Bialas RC, Church FC (2010) Protein C inhibitor regulates both cathepsin L activity and cell-mediated tumor cell migration. Biochim Biophys Acta 1800:580–590PubMedCrossRef Fortenberry YM, Brandal S, Bialas RC, Church FC (2010) Protein C inhibitor regulates both cathepsin L activity and cell-mediated tumor cell migration. Biochim Biophys Acta 1800:580–590PubMedCrossRef
50.
Zurück zum Zitat Reiser J, Oh J, Shirato I et al (2004) Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 279:34827–34832PubMedCrossRef Reiser J, Oh J, Shirato I et al (2004) Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 279:34827–34832PubMedCrossRef
51.
Zurück zum Zitat Chung JH, Im EK, Jin TW et al (2011) Cathepsin L derived from skeletal muscle cells transfected with bFGF promotes endothelial cell migration. Exp Mol Med 43:179–188PubMedCrossRef Chung JH, Im EK, Jin TW et al (2011) Cathepsin L derived from skeletal muscle cells transfected with bFGF promotes endothelial cell migration. Exp Mol Med 43:179–188PubMedCrossRef
52.
Zurück zum Zitat Schlappack OK, Zimmermann A, Hill RP (1991) Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. Br J Cancer 64:663–670PubMedCrossRef Schlappack OK, Zimmermann A, Hill RP (1991) Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. Br J Cancer 64:663–670PubMedCrossRef
53.
Zurück zum Zitat Steffan JJ, Snider JL, Skalli O, Welbourne T, Cardelli JA (2009) Na+/H+ exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells. Traffic 10:737–753PubMedCrossRef Steffan JJ, Snider JL, Skalli O, Welbourne T, Cardelli JA (2009) Na+/H+ exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells. Traffic 10:737–753PubMedCrossRef
Metadaten
Titel
Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells
verfasst von
Dhivya R. Sudhan
Dietmar W. Siemann
Publikationsdatum
01.10.2013
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 7/2013
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-013-9590-9

Weitere Artikel der Ausgabe 7/2013

Clinical & Experimental Metastasis 7/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.